Merck has announced the acquisition of Verona Pharma for 10 billion dollars, strengthening its portfolio of respiratory treatments.
Raluca Ioana Draghici
.webp)
Economy
www.shutterstock.com
Always see our news on Google
Pharmaceutical giant Merck has decided to acquire the British company Verona Pharma for about 10 billion dollars, paying 107 dollars per share, a 23% premium. The strategic move comes amid Merck's desire to diversify its revenue streams, given that the patent for its Keytruda oncology treatment will expire in 2028. This is a continuation of Merck's efforts to expand its portfolio, given previous acquisitions including Prometheus Biosciences.
Sources
Latest News
12:41
India proposes extending tax incentives for foreign companies that supply equipment to local manufacturers until 2041, a measure considered beneficial for Apple.
12:40
The European fund for expanding technology companies starts investments, with an interest of 5 billion euros
12:37
Romania joins the Carpathian Initiative for regional cooperation, launched by Volodymyr Zelensky
12:36
Cristian Bușoi, Secretary of State in the Ministry of Energy, stated that the supply of fuels has improved compared to two weeks ago.
12:35
Denmark has extended mandatory military service from four to 11 months, in the context of European security / The Princess of Denmark enlists in the army at 19 years old
See more news
NEWS ON THE SAME TOPICS
International
AstraZeneca, negotiations with Bristol Myers Squibb for a possible merger that could create a 400 billion dollar group
International
Alphabet announces the sale of shares up to 80 billion dollars to finance the development of artificial intelligence
Personalized news feed, AI-powered search, and notifications in a more interactive experience.
